#cabenuva

[gooddoggirl]

How many drugs from drugs.com's top 100 drugs have you taken?

0

1-5

6-10

11-15

16-20

21-25

26-49

50-100

Voting ended onAug 23, 2025

[pozmagazine]

Canada Is the First to Approve Long-Acting HIV Regimen Cabenuva

The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.

HIV treatment has entered an exciting new era as Canada has become the first nation in the world to approve ViiV Healthcare’s monthly long-acting injectable antiretroviral (ARV) regimen Cabenuva (cabotegravir/rilpivirine)—the first complete regimen for treating the virus that does not require daily pills.

In late December, the Food and Drug Administration (FDA) held up approval of the regimen, citing concerns over its manufacturing process. In turn, ViiV indicated it was working closely with the FDA to address those concerns and ultimately bring Cabenuva to market in the United States.

ViiV first applied for FDA approval of Cabenuva in April 2019.

[the-hem]

💉 Global HIV Prevention: How We Can End HIV with Modern Vaccines & Central Banking 💰

Imagine a world where HIV is no longer a death sentence—where everyone, everywhere, can get vaccinated safely, effectively, and affordably. With the new long-acting HIV shots, this is within reach. We have been waiting all of our lives for this chance to be vaccinated against this deadly disease and the economics are so good. But the Trump Administration has suspended all outlets for this amazing miracle to reach humanity. This has to be remedied and the Crowns are the ones that must do it. This is their holy duty to ensure their capabilities to help mankind to prosper reach every end of this planet.

Current Cutting-Edge Shots

AAV-based HIV vaccine candidates – in phase 3 trials, showing 70–90% protection in high-risk populations.

Cabotegravir long-acting injection (brand: Cabenuva) – already FDA-approved for HIV prevention, given every 2 months.

VRC07-523LS – monoclonal antibody injection providing 6-month protection.

Combination HIV/PrEP long-acting shots – under development, potentially once or twice per year.

How Many Shots Would the World Need?

Target: All adults aged 15+ (~4 billion people)

Frequency: 1–2 doses/year depending on the shot type

Doses/year: 4B (once) → 8B (twice)

Cost to Protect the World

Vaccine cost per dose: $100 (global-scale manufacturing)

Distribution & administration: $20 per dose (cold chain, clinics, healthcare workers)

Total per dose: $120

Global Program Cost

Once per year: 4B × $120 = $480B

Twice per year: 8B × $120 = $960B

Extra for outreach, rural coverage, and monitoring: ~$25–30B

How Central Banking Can Fund It

Central bank sovereign credit issues non-debt, interest-free funds for vaccine production and delivery

Rapid, tax-free deployment worldwide

Fully auditable through WHO, UNICEF, and national health authorities

Insulates the program from market volatility, global crises, and geopolitical pressures

Cost Savings & Economic Impact

Prevented new HIV cases: ~1.35 million per year (if vaccine is 90% effective)

Direct treatment cost savings: ~$6.75B/year

Indirect benefits: healthier workforce, higher productivity, reduced hospitalization, reduced social welfare costs

Multiplier effect: GDP growth, increased household income, higher tax revenue

Legislation Needed

Global HIV Prevention Act (GHIVPA)

Authorizes central banks to fund universal HIV vaccination via sovereign credit.

Covers vaccine procurement, distribution, administration, and monitoring.

Ensures ethical, equitable distribution without discrimination.

Requires annual independent audit and quarterly reporting to global health authorities.

Establishes immediate rollout within 12 months of enactment.

Why This Will Save Lives AND Money

One-time investment in prevention prevents lifelong treatment costs.

Centralized funding eliminates reliance on donor fatigue or taxes.

Protects populations in low-income countries, rural areas, and conflict zones.

Strengthens global health security and workforce productivity.

Call to Action

Support legislation like GHIVPA

Fund global vaccine access using innovative central bank methods

Protect the world’s population and economy from HIV

[gwydionmisha]

FDA Approves Cabenuva, First Long-Acting Injectable HIV Regimen

The treatment will replace daily pills for some people living with HIV.

[pozmagazine]

Women With HIV Interested in Long-Acting Injectable Treatment

A majority of women interviewed in a small study expressed a preference for monthly injectable treatment over daily pills.

A small study of women living with HIV found that a majority said they would prefer to receive monthly injectable antiretroviral (ARV) treatment over a daily pill regimen.

Canada recently became the first nation to approve ViiV Healthcare’s long-acting injectable regimen Cabenuva (cabotegravir/rilpivirine), which is provided as a shot into the muscle by a health care provider once a month.

In December, the U.S. Food and Drug Administration (FDA) declined to approve Cabenuva, citing concerns over its manufacturing. ViiV has indicated that it is working with the FDA to address those concerns.